Phase 3 Readout
RLMD: Phase 3 Topline: A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Mu
June 30, 2028 · ndv-01. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2028
- Company
- RELMADA THERAPEUTICS, INC. (RLMD)
- Drug
- ndv-01
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Mu
- Drug
- ndv-01
- Indication
- Urothelial Carcinoma Bladder; Urothelial Carcinoma Recurrent; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)